Harbour Biomed has initiated a long-term collaboration with Lannacheng to move ahead with next-generation radionuclide drug conjugates. The collaboration aims to develop targeted cancer treatments, delivering precision medicine solutions tailored to improve outcomes for patients. In addition to this, the collaboration will make use of the knowledge that both firms have acquired. The design of radiopharmaceuticals and the development of oncology medications. As a result of the collaboration initiated by Harbour Biomed with Lannacheng, scientists will work together. To examine novel approaches to drug conjugates that will selectively attack cancer cells without affecting normal cells.
Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed. commented in a separate statement,“We are very pleased to establish a long-term strategic collaboration. With Lannacheng, to jointly advance the development of next-generation RDCs. Harbour BioMed is commit to providing efficient and highly differentiated antibody solutions for innovative. Therapies through our globally leading Harbour Mice® fully human antibody platform. This collaboration will deeply integrate Harbour BioMed’s expertise in antibody discovery with Lannacheng’s strengths in radiopharmaceutical R&D and commercialization. Accelerating the development of more precise, effective, and safe cancer therapies and bringing new hope to patients worldwide.”
Strengthening Radiopharmaceutical and Antibody Innovation
The collaboration focuses on the synergy between the radiochemistry capability of Lannacheng. The platform of Harbour Biomed for antibody and peptide-based therapies. For this reason, the collaboration speeds up the development cycle for promising compounds in this context. In addition, this case is in line with the rising need for next-generation targeted cancer therapies.
Wu Xiaoming, General Manager of Lannacheng. Said in a separate statement, “We are pleased to form a long-term strategic collaboration. With Harbour BioMed to advance next-generation radiopharmaceutical R&D. By combining Lannacheng’s radiopharmaceutical capabilities with Harbour BioMed’s antibody discovery expertise. We aim to accelerate the development of precise, safe, and effective cancer therapies, bringing new hope to patients worldwide.”
In conclusion, the Harbour Biomed partnership is a great move forward in the innovation of targeted therapies for cancer. Through the union of resources & scientific expertise, the two firms hope to provide the market with the “best-of-the-best” radionuclide therapies.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: PRNewswire.com
